Showing 2761-2770 of 5621 results for "".
- Second Sight to Accelerate Development of Orion Visual Cortical Prosthesis Systemhttps://modernod.com/news/second-sight-to-accelerate-development-of-orion-visual-cortical-prosthesis-system/2476589/Second Sight Medical Products announced its plan to accelerate the development and commercialization of its Orion Visual Cortical Prosthesis System. Orion holds the potential to provide useful artificial vision to individuals blind from many causes, including glaucoma, eye injury, diabetic retino
- MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiencyhttps://modernod.com/news/meiragtx-announces-positive-6-month-data-from-phase-1-2-trial-of-investigational-gene-therapy-aav-rpe65-for-rpe65-deficiency/2476582/MeiraGTx Holdings announced positive data from a phase 1/2 dose escalation trial of AAV-RPE65, the company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to tre
- Novartis to Acquire Dry Eye Drug Xiidra in Deal Worth Up to $5.3 Billionhttps://modernod.com/news/novartis-to-acquire-dry-eye-drug-xiidra-in-deal-worth-up-to-5-3-billion/2476567/In one of the largest ophthalmic drug deals to date, Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda Pharmaceutical in a deal worth up to $5.3 billion. Under terms of the deal, Novartis will pay $3.4 billi
- Genentech: Pivotal Phase 3 Data for Neuromyelitis Optica Spectrum Disorder (Devic’s Disease)https://modernod.com/news/genentech-pivotal-phase-3-data-for-neuromyelitis-optica-spectrum-disorder-devics-disease/2476566/Genentech presented new pivotal phase 3 data for the rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), also known as Devic’s Disease, for which there are no approved treatments. NMOSD is a rare, lifelong and debilitating autoimmune disease of the c
- Preclinical Studies Demonstrate Galimedix’s GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Modelshttps://modernod.com/news/preclinical-studies-demonstrate-galimedixs-gal-101-shows-neuroprotective-effect-from-toxic-amyloid-beta-in-dry-amd-and-glaucoma-models/2476564/Galimedix Therapeutics presented data demonstrating its novel, first-in-class, investigational compound GAL-101 provides neuroprotection from misfolded amyloid beta molecules aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues. Further, investiga
- Ophtec Receives FDA Approval for RingJect Design Enhancementshttps://modernod.com/news/ophtec-receives-fda-approval-for-ringject-design-enhancements/2476536/Ophtec USA received FDA approval for the RingJect delivery system design optimization changes. Ophtec’s RingJect is a single use injector preloaded with the Ophtec Capsular Tension Ring (CTR). The Ophtec CTR is made of PMMA with patented compression molding technology, making for a durable
- IBM’s New AI Technique Could Detect Glaucoma Earlierhttps://modernod.com/news/ibms-new-ai-technique-could-detect-glaucoma-earlier/2476530/At ARVO, IBM researchers presented new techniques in deep learning that could help unlock earlier glaucoma detection. IBM and NYU’s research demonstrates how deep learning models can be trained to learn from and analyze easily-obtained retina images, and then use this analysis to directly estimat
- EyePoint Pharmaceuticals Presents Positive Yutiq 36-Month Follow-Up Phase 3 Data at ARVOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutiq-36-month-follow-up-phase-3-data-at-2019-arvo-annual-meeting/2476523/EyePoint Pharmaceuticals announced the presentation of 36-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18-mg micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The data
- RadianceTx Expands Team to Develop Beta Ophthalmic Systemhttps://modernod.com/news/radiancetx-expands-team-to-develop-beta-ophthalmic-system/2476511/Radiance Therapeutics has announced the expansion of its core team. Abigail Mackrill, formerly of Ophthalmology Futures Forums and The Ophthalmologist, joins as Director of Business Development and Outreach. James Fazio, MBA, Msc Eng, formerly Global Business Leader for
- LIGHTMED Appoints Lee Walker-Roberts as Global Business Development Directorhttps://modernod.com/news/lightmed-appoints-lee-walker-roberts-as-global-business-development-director/2476484/LIGHTMED announced the appointment of Lee Walker-Roberts as Global Business Development Director, effective immediately. Mr. Walker-Roberts is an experienced leader and executive advisor for high-tech companies ranging from privately-owned start-ups to companies with over $200 million in annual s